Recent reports indicate that cells derived from acute myeloid leukemia (AML) patients can be effectively targeted with a BCL-2 and/or MCL-1 inhibitor, [11, 13–15] although other studies suggest that these cells depend primarily on BCL-2 for survival. This evidence concerns the gene MCL1 and acute myeloid leukemia.